1.Epidemiology of paediatric intensive care unit admissions, deaths and organ donation candidacy: A single-centre audit.
John Zhong Heng LOW ; Joel Kian Boon LIM ; Herng Lee TAN ; Rudimar Martinez FERNANDEZ ; Samsudin Bin NORDIN ; Yee Hui MOK ; Judith Ju-Ming WONG
Annals of the Academy of Medicine, Singapore 2024;54(1):17-26
INTRODUCTION:
There are limited reports on the epidemiology of paediatric intensive care unit (PICU) admissions, deaths and organ donation candidacy. We aimed to describe PICU admission characteristics and outcomes, determine risk factors for mortality, and perform an independent assessment of missed organ donation opportunities.
METHOD:
We adopted a clinical audit design recruiting consecutive patients admitted to a single-centre multidisciplinary PICU from June 2020 to December 2023. Clinical characteristics and outcomes of survivors and non-survivors were described. Multivariable regression was performed to identify independent risk factors for mortality. Organ donation candidacy was evaluated by an independent team based on the criteria by Singapore's National Organ Transplant Unit.
RESULTS:
There were 1766 PICU admissions with mean age ± standard deviation of 5.9 ± 6.0 years. Surgical admissions accounted for 707/1766 (40%), while the most common medical admission category was respiratory (416/1766; 23.6%). The majority of 983/1766 (55.7%) had a chronic comorbidity and 312/1766 (17.6%) were dependent on at least 1 medical technology device. Mortality occurred in 99/1766 (5.6%). After adjusting for elective admissions and admission category; comorbidity with adjusted odds ratio (aOR) 95% confidence interval (CI) 3.03 (1.54-5.96); higher Pediatric Index of Mortality 3 (PIM 3) score with aOR 1.06 (95% CI 1.04-1.08); and functional status scale with aOR 1.07 (95% CI 1.00-1.13) were associated with mortality. Among non-survivors, organ donor candidacy was 21/99 (21.2%) but successful organ donation occurred in only 2/99 (2.0%).
CONCLUSION
In this single-centre audit, comorbidities, PIM 3 score and functional impairment were associated with mortality. Efforts are needed to improve paediatric organ donation rates.
Humans
;
Male
;
Female
;
Tissue and Organ Procurement/statistics & numerical data*
;
Intensive Care Units, Pediatric/statistics & numerical data*
;
Child, Preschool
;
Child
;
Infant
;
Singapore/epidemiology*
;
Risk Factors
;
Patient Admission/statistics & numerical data*
;
Hospital Mortality
;
Adolescent
;
Medical Audit
;
Comorbidity
;
Clinical Audit
2.Immunomodulator use in paediatric severe sepsis and septic shock.
Alpha Omega Cheng Jin LEE ; Ashley Hsi Yin CHUA ; Rehana SULTANA ; Jan Hau LEE ; Judith Ju Ming WONG
Annals of the Academy of Medicine, Singapore 2021;50(10):765-772
INTRODUCTION:
The use of drugs that modulate the immune system during paediatric severe sepsis and septic shock may alter the course of disease and is poorly studied. This study aims to characterise these children who received immunomodulators and describe their clinical outcomes.
METHODS:
This is a retrospective chart review of patients with severe sepsis and septic shock admitted into the paediatric intensive care unit (PICU). Clinical, haematological and outcome characteristics of patients with or without exposure to immune-modulating drugs were compared. Primary outcome was PICU mortality; secondary outcomes were 28-day ventilator-free days (VFD) and intensive care unit-free days (IFD). Univariate and multivariable analyses were performed for these outcomes.
RESULTS:
A total of 109 patients with paediatric severe sepsis or septic shock were identified. Of this number, 47 (43.1%), 16 (14.7%) and 3 (2.8%) patients received systemic corticosteroids, intravenous immunoglobulins and granulocyte colony stimulating factor, respectively. Patients who received immune-modulating drugs were more likely to require invasive ventilation (38/54 [70.4%] versus 26/55 [47.3%],
CONCLUSION
Immune-modulating drugs were frequently used in paediatric severe sepsis and septic shock. Patients who received these drugs seemed to require more PICU support. Further studies are required to examine this association thoroughly.
Child
;
Humans
;
Immunologic Factors/therapeutic use*
;
Intensive Care Units, Pediatric
;
Retrospective Studies
;
Sepsis/drug therapy*
;
Shock, Septic/drug therapy*

Result Analysis
Print
Save
E-mail